ID: ALA35919

Max Phase: Preclinical

Molecular Formula: C11H11NO4S

Molecular Weight: 253.28

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(C2=N[C@@H](C(=O)O)CS2)c(O)c1

Standard InChI:  InChI=1S/C11H11NO4S/c1-16-6-2-3-7(9(13)4-6)10-12-8(5-17-10)11(14)15/h2-4,8,13H,5H2,1H3,(H,14,15)/t8-/m1/s1

Standard InChI Key:  GTXYNYMQHRMYQR-MRVPVSSYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 253.28

Molecular Weight (Monoisotopic): 253.0409

AlogP: 1.35

#Rotatable Bonds: 3

Polar Surface Area: 79.12

Molecular Species: ACID

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.02

CX Basic pKa: 0.81

CX LogP: 2.22

CX LogD: -1.26

Aromatic Rings: 1

Heavy Atoms: 17

QED Weighted: 0.85

Np Likeness Score: 0.90

References

1. Bergeron RJ, Wiegand J, McManis JS, Bussenius J, Smith RE, Weimar WR..  (2003)  Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency.,  46  (8): [PMID:12672247] [10.1021/jm020412d]

2. Bergeron RJ, Wiegand J, McManis JS, Weimar WR, Park JH, Eiler-McManis E, Bergeron J, Brittenham GM..  (2005)  Partition-variant desferrithiocin analogues: organ targeting and increased iron clearance.,  48  (3): [PMID:15689166] [10.1021/jm049306x]

3. Bergeron RJ, Wiegand J, McManis JS, Vinson JR, Yao H, Bharti N, Rocca JR..  (2006)  (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.,  49  (9): [PMID:16640338] [10.1021/jm0508944]

4. Bergeron RJ, Wiegand J, McManis JS, Bharti N..  (2006)  The design, synthesis, and evaluation of organ-specific iron chelators.,  49  (24): [PMID:17125256] [10.1021/jm0608816]

Source

Source(1):

• Scientific Literature